Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 05/29/2007) - Patients with T-cell or B-cell lymphoid cancers that have recurred or progressed despite prior chemotherapy will receive the drug ABT-263 orally for up to a year in this phase I/II clinical trial.
Monoclonal Antibody Therapy for Treatment-Resistant Blood Cancers
(Posted: 03/29/2005, Updated: 05/16/2007) - This phase I dose-escalation study is investigating safety and tolerability of siplizumab, and will determine the maximum dose that can be given to patients with CD2-positive lymphoproliferative disease.
Romidepsin for T-Cell Lymphoma
(Posted: 01/13/2004, Updated: 05/01/2007) - With this trial, researchers are seeking to determine whether romidepsin (depsipeptide, FR901228), a histone deacetylase inhibitor, can help bring about remission in patients with T-cell lymphoma.
Preventing Bladder Cancer Recurrence and Progression
(Posted: 12/07/2004, Updated: 04/26/2007) - In this study, two types of drugs are being evaluated to see whether they are effective in preventing bladder cancer recurrence and progression after surgery in patients with a history of smoking.
Combination Therapy for Peritoneal Carcinomatosis
(Posted: 03/21/2006, Updated: 04/26/2007) - In this clinical trial, patients with peritoneal carcinomatosis from low-grade gastrointestinal cancers will be treated with surgery to remove all visible tumors (operative debulking). During surgery, half of the patients will also be treated with hyperthermic chemotherapy administered directly into the peritoneal cavity (continuous hyperthermic peritoneal perfusion).